PetMedix joins Zoetis to bring the benefits of species-specific antibody therapies to pet owners
PetMedix, a leader in discovering species-specific therapeutic antibodies for pets, announced that it has been acquired by Zoetis, the world’s leading animal health company. Both parties have collaborated since 2022 with respect to antibody discovery.
PetMedix enters into antibody discovery collaboration with Zoetis
PetMedix™ is pleased to announce a collaboration with Zoetis to develop novel, fully species-specific companion animal monoclonal antibody therapeutics (mAbs) using PetMedix's proprietary transgenic platforms.
PetMedix raises £27m Series B
PetMedix™ announces today the completion of an oversubscribed £27m ($37m) Series B financing round that will be used to advance its innovative pipeline through clinical development.
PetMedix monoclonal antibodies outperform benchmarks in canine study
Successful performance of first-ever fully canine antibodies in dog trial paves the way for next-generation technology to meet therapeutic needs in fast-growing pet health market.
PetMedix announces completion of the Ky9™ canine antibody discovery platform
Scientists working in the labs of PetMedix Ltd have recently achieved the successful transfer of more than 4 Mbp of canine antibody DNA into the mouse genome. This process involved 35 separate genetic manipulation steps, in what is likely to be the largest transfer of genetic material from one mammalian species to another, not involving human DNA.
PetMedix co-founder Jolyon Martin named in Forbes '30 Under 30' list
Dr Jolyon Martin, Co-Founder and Head of Business Development at animal health start-up, PetMedix Ltd, has been named in the Forbes 30 Under 30 Europe List for Science and Healthcare 2021.
PetMedix partners with Boehringer Ingelheim
PetMedix is pleased to announce a multi-year partnership with Boehringer Ingelheim to develop novel and transformative companion animal antibody therapeutics using PetMedix's proprietary Ky9™ platform.